CA3173126A1 - Nucleic acid sequences encapsulated in lipid nanoparticles - Google Patents
Nucleic acid sequences encapsulated in lipid nanoparticles Download PDFInfo
- Publication number
- CA3173126A1 CA3173126A1 CA3173126A CA3173126A CA3173126A1 CA 3173126 A1 CA3173126 A1 CA 3173126A1 CA 3173126 A CA3173126 A CA 3173126A CA 3173126 A CA3173126 A CA 3173126A CA 3173126 A1 CA3173126 A1 CA 3173126A1
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- aspects
- pharmaceutically acceptable
- lipid nanoparticle
- cedna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000990P | 2020-03-27 | 2020-03-27 | |
| US63/000,990 | 2020-03-27 | ||
| PCT/US2021/024413 WO2021195529A2 (en) | 2020-03-27 | 2021-03-26 | Novel lipids and nanoparticle compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3173126A1 true CA3173126A1 (en) | 2021-09-30 |
Family
ID=77890624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3173126A Pending CA3173126A1 (en) | 2020-03-27 | 2021-03-26 | Nucleic acid sequences encapsulated in lipid nanoparticles |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12534435B2 (enExample) |
| EP (1) | EP4125821A4 (enExample) |
| JP (2) | JP7746280B2 (enExample) |
| KR (1) | KR20220160647A (enExample) |
| CN (1) | CN115916163A (enExample) |
| AU (1) | AU2021241696A1 (enExample) |
| BR (1) | BR112022019369A2 (enExample) |
| CA (1) | CA3173126A1 (enExample) |
| IL (1) | IL296763B2 (enExample) |
| MX (1) | MX2022011988A (enExample) |
| WO (1) | WO2021195529A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024192528A1 (en) * | 2023-03-22 | 2024-09-26 | Nanovation Therapeutics Inc. | Ionizable anionic lipids |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| JP7746280B2 (ja) | 2020-03-27 | 2025-09-30 | ジェネレーション バイオ カンパニー | 新規脂質及びそれらのナノ粒子組成物 |
| AU2021307952A1 (en) * | 2020-07-17 | 2023-03-02 | Generation Bio Co. | Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| CA3234321A1 (en) * | 2021-09-30 | 2023-04-06 | Nof Corporation | Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells |
| EP4452942A1 (en) * | 2021-12-20 | 2024-10-30 | Beam Therapeutics Inc. | Nanomaterials comprising disulfides |
| WO2023190175A1 (ja) | 2022-03-28 | 2023-10-05 | 日油株式会社 | 末梢血単核細胞へ核酸を送達するための脂質ナノ粒子およびこれを用いて末梢血単核細胞へ核酸を送達する方法 |
| US20260115316A1 (en) | 2022-03-28 | 2026-04-30 | Nof Corporation | Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same |
| JPWO2023190164A1 (enExample) * | 2022-03-28 | 2023-10-05 | ||
| WO2023190170A1 (ja) | 2022-03-28 | 2023-10-05 | 日油株式会社 | 核酸内封脂質ナノ粒子の製造方法及びこれを含む医薬品組成物の製造方法、並びに、核酸を細胞内又は標的細胞内に導入する方法 |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| CN119604276A (zh) | 2022-07-15 | 2025-03-11 | 日油株式会社 | 脂质纳米粒子及其制造方法、封入有核酸的脂质纳米粒子及其制造方法以及使用封入有核酸的脂质纳米粒子赋予生物体获得性免疫的方法 |
| CA3262131A1 (en) | 2022-07-15 | 2025-06-13 | Nof Corporation | FREEZE-DRIED COMPOSITION OF LIPID NANOPARTICLES CHARGED WITH NUCLEIC ACID |
| CN120957730A (zh) | 2023-03-29 | 2025-11-14 | 国立大学法人东北大学 | 核酸封装脂质纳米粒子的制造方法 |
| CN116082184B (zh) * | 2023-04-12 | 2023-06-30 | 山东大学 | 基于环己二胺的可电离脂质、脂质纳米颗粒及其制备方法与应用 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025043146A2 (en) * | 2023-08-24 | 2025-02-27 | Molecular Axiom Inc. | Lipid nanoparticle compositions and methods of using same |
| CN121263400A (zh) * | 2023-12-15 | 2026-01-02 | 厦门赛诺邦格生物科技股份有限公司 | 一种含二硫键的可降解阳离子脂质及其应用 |
| CN117964577B (zh) * | 2024-03-29 | 2024-06-21 | 天津全和诚生物技术有限公司 | 阳离子脂质化合物、其制备方法、包含其的组合物及应用 |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026070952A1 (ja) * | 2024-09-27 | 2026-04-02 | 日油株式会社 | ジスルフィド結合を有する化合物およびその製造方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| AU733310C (en) | 1997-05-14 | 2001-11-29 | University Of British Columbia, The | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US7201898B2 (en) | 2000-06-01 | 2007-04-10 | The University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
| WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| EP1664316B1 (en) | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| CN101267805A (zh) | 2005-07-27 | 2008-09-17 | 普洛体维生物治疗公司 | 制造脂质体的系统和方法 |
| CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| US8883211B2 (en) | 2008-07-10 | 2014-11-11 | Serina Therapeutics, Inc. | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
| US20130037977A1 (en) | 2010-04-08 | 2013-02-14 | Paul A. Burke | Preparation of Lipid Nanoparticles |
| US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| WO2012024526A2 (en) | 2010-08-20 | 2012-02-23 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
| WO2012046265A1 (ja) * | 2010-10-05 | 2012-04-12 | トヨタ自動車株式会社 | 推定装置および推定方法 |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| EP3485875A1 (en) | 2011-11-04 | 2019-05-22 | Nitto Denko Corporation | Single use system for sterelily producing lipid-nucleic acid particles |
| WO2013073480A1 (ja) | 2011-11-18 | 2013-05-23 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
| TW201808342A (zh) | 2012-05-02 | 2018-03-16 | 喜納製藥公司 | 包含四ｇａｌｎａｃ之新穎結合物及傳送寡核苷酸之方法 |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| BR112018003910B1 (pt) | 2015-11-16 | 2022-03-22 | F. Hoffmann-La Roche Ag | Derivado de fosforamidita galnac, processo para a preparação de um derivado de fosforamidita galnac de fórmula i e uso dos derivados de fosforamidita galnac de fórmula i |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| WO2017117528A1 (en) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| MX2018010633A (es) | 2016-03-03 | 2019-06-13 | Univ Massachusetts | Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral. |
| CN111902397B (zh) | 2018-03-27 | 2024-04-12 | 日油株式会社 | 改进了细胞内动力学的阳离子脂质 |
| JP7075256B2 (ja) * | 2018-03-28 | 2022-05-25 | 三菱重工業株式会社 | 配管の余寿命評価方法 |
| WO2021046265A1 (en) | 2019-09-06 | 2021-03-11 | Generation Bio Co. | Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof |
| JP7746280B2 (ja) * | 2020-03-27 | 2025-09-30 | ジェネレーション バイオ カンパニー | 新規脂質及びそれらのナノ粒子組成物 |
| AU2021307952A1 (en) * | 2020-07-17 | 2023-03-02 | Generation Bio Co. | Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof |
-
2021
- 2021-03-26 JP JP2022558110A patent/JP7746280B2/ja active Active
- 2021-03-26 CA CA3173126A patent/CA3173126A1/en active Pending
- 2021-03-26 IL IL296763A patent/IL296763B2/en unknown
- 2021-03-26 BR BR112022019369A patent/BR112022019369A2/pt unknown
- 2021-03-26 CN CN202180037847.5A patent/CN115916163A/zh active Pending
- 2021-03-26 MX MX2022011988A patent/MX2022011988A/es unknown
- 2021-03-26 WO PCT/US2021/024413 patent/WO2021195529A2/en not_active Ceased
- 2021-03-26 KR KR1020227037604A patent/KR20220160647A/ko active Pending
- 2021-03-26 EP EP21776608.8A patent/EP4125821A4/en active Pending
- 2021-03-26 US US17/913,498 patent/US12534435B2/en active Active
- 2021-03-26 AU AU2021241696A patent/AU2021241696A1/en active Pending
-
2024
- 2024-04-24 US US18/644,728 patent/US12252470B2/en active Active
-
2025
- 2025-01-31 US US19/042,351 patent/US20250361208A1/en active Pending
- 2025-09-17 JP JP2025154013A patent/JP2025181861A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024192528A1 (en) * | 2023-03-22 | 2024-09-26 | Nanovation Therapeutics Inc. | Ionizable anionic lipids |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025181861A (ja) | 2025-12-11 |
| US20230159459A1 (en) | 2023-05-25 |
| IL296763A (en) | 2022-11-01 |
| JP2023518985A (ja) | 2023-05-09 |
| IL296763B1 (en) | 2025-12-01 |
| BR112022019369A2 (pt) | 2022-12-13 |
| MX2022011988A (es) | 2023-01-04 |
| EP4125821A2 (en) | 2023-02-08 |
| WO2021195529A3 (en) | 2021-11-18 |
| KR20220160647A (ko) | 2022-12-06 |
| AU2021241696A1 (en) | 2022-12-01 |
| JP7746280B2 (ja) | 2025-09-30 |
| EP4125821A4 (en) | 2024-06-26 |
| CN115916163A (zh) | 2023-04-04 |
| US20250361208A1 (en) | 2025-11-27 |
| US12252470B2 (en) | 2025-03-18 |
| US12534435B2 (en) | 2026-01-27 |
| IL296763B2 (en) | 2026-04-01 |
| WO2021195529A2 (en) | 2021-09-30 |
| US20240294474A1 (en) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12252470B2 (en) | Lipids and nanoparticle compositions thereof | |
| IL323923A (en) | Ionizable lipids and nanoparticle compositions thereof | |
| US12263228B2 (en) | Lipids and compositions thereof | |
| US20240293574A1 (en) | Cationic lipids and compositions thereof | |
| US20230181764A1 (en) | Novel lipids and nanoparticle compositions thereof | |
| CN117545469A (zh) | 阳离子脂质及其组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220923 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250321 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250321 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250321 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250414 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250415 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250613 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250613 |